A putative therapeutic target in glycogen storage disease: O95278

Ablatotech Signals reports today on a putative therapeutic target — O95278 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in glycogen storage disease.

Background

O95278 is a putative target that warrants experimental validation in the context of glycogen storage disease (GSD). This candidate has emerged from expression-profiling studies, suggesting a potential involvement in the metabolic pathways disrupted in GSD. Given the significant impact of glycogen storage diseases on metabolic health, further exploration of O95278 could lead to novel therapeutic approaches.

Data-mining rationale

The identification of O95278 as a candidate target was achieved through a comprehensive analysis of UniProt's reviewed human entries related to "glycogen storage disease," cross-referenced against multiple microarray datasets from the NCBI Gene Expression Omnibus (GEO), including GDS:200293648, GDS:200088839, GDS:200075713, GDS:200082081, and GDS:200031064. This analysis highlighted O95278 as a notable candidate due to its presence in expression-profiling studies. However, it is important to note that there are currently no registered Phase 1 or higher clinical programs associated with this target.

Why prior analyses may have missed this

Many of the GEO datasets utilized in this analysis were generated before the implementation of modern empirical-Bayes statistical methods, such as the limma package, which are essential for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier studies may have led to missed opportunities to identify significant expression changes related to O95278. Re-analysis of these datasets using contemporary statistical techniques could provide a clearer understanding of the gene's role in glycogen storage disease.

Reasoning for further validation

To substantiate the potential of O95278 as a therapeutic target, several experimental approaches are suggested: 1. Re-analyze the matched GEO datasets using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of less than 0.05 to accurately identify differentially expressed genes. 2. Validate the top differentially expressed genes, including O95278, through quantitative PCR (qPCR) in an independent cohort to confirm expression changes. 3. Investigate the tissue specificity of O95278 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess its relevance across different tissues. 4. Utilize pathway analysis tools like STRING or OmniPath to explore the biological pathways in which O95278 may be involved, providing context for its role in glycogen storage disease. 5. If validation is achieved, assess the druggability of O95278 through databases such as DGIdb and ChEMBL to evaluate its potential as a therapeutic target.

References